Drug intelligence / Profile preview

isavuconazole + methotrexate

Development stage: Phase 1
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

**isavuconazole + methotrexate** is a combination of two drugs: isavuconazole, a broad-spectrum triazole antifungal agent, and methotrexate, an antimetabolite and immunosuppressant often used in chemotherapy and autoimmune diseases. Isavuconazole inhibits cytochrome P450-dependent lanosterol 14-alpha-demethylase, thereby blocking the synthesis of ergosterol, a key component of fungal cell membranes, leading to cell death. Methotrexate is a substrate of breast cancer resistance protein (BCRP), organic anion transporter 1/3 (OAT1/OAT3), and acts by inhibiting dihydrofolate reductase, interfering with DNA synthesis, repair, and cellular replication.

Targets

DHFR (Dihydrofolate reductase)CYP51A1 (Sterol 14α-demethylase)SLC47A1 (Multidrug and toxin extrusion transporter 1)

Beyond the preview

Go deeper on isavuconazole + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isavuconazole + methotrexate.